Preferred Label : Epcoritamab;
NCIt synonyms : DuoBody-CD3xCD20; Anti-CD20/CD3 Bispecific Antibody GEN3013; Epcoritamab-bysp;
NCIt definition : A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic
activities. Epcoritamab contains two antigen-recognition sites: one for human CD3,
a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA)
that is exclusively expressed on B-cells during most stages of B-cell development
and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab
binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage
may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing
tumor B-cells.;
UNII : D6OMY2L0WA;
CAS number : 2134641-34-0;
Drug name : Epkinly; Tepkinly;
Molecule name : GEN-3013; GEN 3013;
NCI Metathesaurus CUI : CL973375;
Codes from synonyms : 66092;
Origin ID : C163022;
UMLS CUI : C5418281;
Semantic type(s)
UMLS correspondences (same concept)
chemical_or_drug_has_mechanism_of_action
concept_is_in_subset
has_target
is_component_of_chemotherapy_regimen
https://www.ema.europa.eu/en/medicines/human/EPAR/tepkinly
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Epcoritamab
Epcoritamab
epcoritamab
orphan drug production
drug approval
europe
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
adult
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
recurrence
injections, subcutaneous
risk management
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
aged
drug evaluation, preclinical
---
https://www.has-sante.fr/jcms/p_3501630/fr/tepkinly-epcoritamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
epcoritamab
injections, subcutaneous
Antineoplastic Agents, Immunological
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
adult
Third-Line Therapy
evaluation of the transparency committee
lymphoma, large B-Cell, diffuse
Epcoritamab
---
https://www.has-sante.fr/jcms/p_3453127/fr/epcoritamab-abbvie-epcoritamab-lymphome-diffus-a-grande-cellule-b
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Epcoritamab
bispecific monoclonal antibodies
adult
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
guidelines for drug use
epcoritamab
---
https://ansm.sante.fr/tableau-acces-derogatoire/epcoritamab
2023
false
false
false
France
French
drug information
lymphoma, large B-Cell, diffuse
Epcoritamab
epcoritamab
---
https://ansm.sante.fr/tableau-marr/epcoritamab
2023
false
false
false
France
French
risk management
bispecific monoclonal antibodies
Epcoritamab
patients guideline
Cytokine Release Syndrome
signs and symptoms
Immune Effector Cell Associated Neurotoxicity Syndrome
cell-associated neurotoxicity
drug information
epcoritamab
---